Live Tonight: China's First Peripheral Constrained Drug-Coated Balloon – Matrix Super PTX® by Biotronik Medical | Artery Innovation Showcase Episode 102

For endovascular therapy of lower extremity arteries, in recent years"Intervention Without Implantation"The clinical benefits and treatment concepts are increasingly recognized by a wide range of experts,Peripheral Drug-Coated BalloonThe usage volume is increasing day by day, but there are still some pain points in the use of drug-coated balloons, such as: flow-limiting dissection may occur during vessel preparation, residual stenosis and elastic recoil still exist after drug-coated balloon dilation, and there is a high probability that rescue stent implantation will be required.

Based on the pain points in clinical treatment and the limitations of existing technologies,Batai Medical Technology Co., Ltd.(hereinafter referred to as "Batai Medical") independently developed“Peripheral Constrained Drug-Coated Balloon Dilatation Catheter Matrix Super PTX”^®”It was approved for market launch by the National Medical Products Administration on July 30, 2024.Matrix Super PTX^®It is China’s first peripheral constrained drug-coated balloon and currently the only such product available in the Chinese market. It marks the first time that a perfect integration has been achieved between lumen preparation devices and lumen treatment products for endovascular therapy of peripheral arteries.

On Wednesday, October 16, at 19:30, the 102nd episode of VCBeat New Product Review will feature Zheng Hai, Marketing Director and Medical Affairs Director at Baitai Medical, who will present“China’s First Peripheral Constrained Drug-Coated Balloon Matrix Super PTX”^®”Product Promotion.

Matrix Super PTX Peripheral Constrained Drug-Coated Balloon Dilatation Catheter^®

Matrix Super PTX^®Perfectly CombinesPeripheral Constrained Balloons and Peripheral Drug-Coated BalloonsFeatures and Advantages: ItsEquipped with Matrix Super^®Peripheral Constraint Balloon Platform, featuring a unique nitinol wire structure. During inflation, as pressure increases, the balloon surface is constrained by the wires, resulting in an orderlyConvex-Concave Structurenamely the occipital region and the decompression groove, thereby enabling the balloon to performControlled, atraumatic, and uniform dilation effectively expands the lesion while significantly reducing the incidence of flow-limiting dissections.; meanwhile, leveraging the constrained balloon platform, the drug coating can better conform to the vessel wall, thereby facilitating rapid drug release and transfer, maintaining therapeutic concentrations in the vessel wall over the long term, and ensuring sustained luminal patency.

Matrix Super PTX^®It is China's first peripherally constrained drug-coated balloon., achieving for the first time the perfect integration of lumen preparation and therapeutic functions in endovascular treatment of peripheral arteries.Matrix Super PTX^®'s unique design enables a single product to deliver the clinical outcomes of both a constrained balloon and a drug-coated balloon, facilitating one-stop luminal preparation and treatment, while featuringHigher cost-effectiveness, simpler operation, shorter procedure time, lower radiation exposure, and effective reduction in the need for bailout stent implantation.

Matrix Super PTX^®The launch marks a significant step forward for China in the field of high-performance vascular interventional devices, not onlyBreaking the Monopoly of International Brands, and also provide more options and a better treatment experience for doctors and patients.

Scan the QR code on the poster to add the assistant and reserve a spot for the live broadcast.

Zheng Hai

Director of Marketing, Baitai Medical &Director of Medical Affairs

Shanghai Jiao Tong University School of Medicine, M.D.

Cardiothoracic Surgeon, Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine

Visiting Scholar, Department of Biomedical Engineering, Purdue University, USA

Previously held positions at Medtronic (Shanghai) Management Co., Ltd., Abbott Medical Device Trading (Shanghai) Co., Ltd., and Contec Medical Systems (Shanghai) Co., Ltd., where responsibilities included market management and professional education.

Batai Medical Technology Co., Ltd. (hereinafter referred to as “Batai Medical”) was established in August 2015, with its headquarters located at the Hangzhou Biopharmaceutical Port in China. As a national-level high-tech enterprise, Batai Medical specializes in the research and development, manufacturing, and sales of medical devices in the field of vascular intervention. The company’s main products include coronary drug-coated balloons, peripheral drug-coated balloons, coronary PTCA balloons, peripheral PTA balloons, peripheral drug-eluting stents, as well as accompanying introducer sheaths, angiographic catheters, and guiding catheters.

Batai Medical holds significant advantages in technological R&D, possessing over 50 patents and having obtained multiple Class III NMPA registration certificates as well as EU CE certifications. In terms of products, Batai Medical’s independently developed Matrix Super PTX^®Peripheral Constrained Drug-Coated Balloon, Matrix Super^®Peripheral constrained balloon, Yintai peripheral drug-coated balloon, and Ultra Huangtai^®The second-generation peripheral double-layer high-pressure balloon has been successively approved for market launch this year, marking a further breakthrough and strategic expansion by Batai Medical in the field of peripheral vascular interventional devices.

Currently, the Company has secured entry into the Special Review Procedure for Innovative Medical Devices (i.e., the “Green Channel”) for three products in China and has undertaken multiple key R&D projects. Through sustained, high-intensity R&D investment and independent innovation, Batai Medical has established a product portfolio with international competitiveness.

Leveraging its deep expertise and innovation in the field of vascular intervention, Botai Medical is steadily evolving into a platform enterprise specializing in high-performance vascular interventional devices, dedicated to providing safer and more effective treatment solutions for patients worldwide.

“Artery New Product Showcase” is a live-streaming program designed to support medical enterprises in launching innovative products. The program’s mission is to facilitate the milestone launch of every innovative medical product. If your company has plans to release an innovative medical product or achieve a significant milestone and wishes to participate in the “Artery New Product Showcase,” please add our assistant for consultation.

Scan the QR code below to contact the assistant and schedule a live stream (if already added, please proactively message the assistant).

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Send a screenshot of the live stream to the assistant to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight Industry Think Tank].